Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2021 Dec 21;42(48):4964-4977.
doi: 10.1093/eurheartj/ehab618.

Cardiovascular immunotoxicities associated with immune checkpoint inhibitors: a safety meta-analysis

Charles Dolladille  1 , Julia Akroun  2 , Pierre-Marie Morice  3 , Anne Dompmartin  2 , Emilien Ezine  2 , Marion Sassier  4 , Angélique Da-Silva  5 , Anne-Flore Plane  6 , Damien Legallois  7 , Jean-Mathieu L'Orphelin  2 , Joachim Alexandre  1
Affiliations
Meta-Analysis

Cardiovascular immunotoxicities associated with immune checkpoint inhibitors: a safety meta-analysis

Charles Dolladille et al. Eur Heart J. .

Abstract

Aims: The risk and incidence of cardiovascular (CV) immune-related adverse events (irAEs) associated with immune checkpoint inhibitors (ICIs) in cancer patients remain unknown.

Methods and results: We systematically reviewed all randomized clinical trials (RCTs) including at least one ICI-containing arm and available CV adverse event (CVAE) data in cancer patients in the ClinicalTrials.gov registry, Medline, and the Cochrane CENTRAL Register of Controlled Trials, up to 31 August 2020 (CRD42020165672). The primary outcome was the summary risk of 16 different CVAEs associated with ICI exposure vs. controls (placebo and non-placebo) in RCTs. CVAEs with an increased risk associated with ICI exposure were considered as CV irAEs. Summary incidences of CV irAEs identified in our primary outcome analyses were computed using all RCTs including at least one ICI-containing arm. We used a random-effects meta-analysis to obtain Peto odds ratios (ORs) with 95% confidence intervals (CIs) and logit transformation and inverse variance weighting to compute summary incidences. Sixty-three unique RCTs with at least one ICI-containing arm (32 518 patients) were retrieved, among which 48 (29 592 patients) had a control arm. Among the 16 CVAEs studied, ICI use was associated with an increased risk of 6 CV irAEs including myocarditis, pericardial diseases, heart failure, dyslipidemia, myocardial infarction, and cerebral arterial ischaemia with higher risks for myocarditis (Peto OR: 4.42, 95% CI: 1.56-12.50, P < 0.01; I2 = 0%, P = 0.93) and dyslipidemia (Peto OR: 3.68, 95% CI: 1.89-7.19, P < 0.01; I2 = 0%, P = 0.66). The incidence of these CVAEs ranged from 3.2 (95% CI 2.0-5.1) to 19.3 (6.7-54.1) per 1000 patients, in studies with a median follow-up ranging from 3.2 to 32.8 months.

Conclusion: In RCTs, ICI use was associated with six CV irAEs, not confined to myocarditis and pericarditis.

Keywords: Cancer; Cardiovascular adverse event; Immune checkpoint inhibitor; Randomized clinical trials; Safety meta-analysis.

PubMed Disclaimer

Comment in

Substances